This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

CHARLES R. AUSTRIAN, M.D.; WILLIAM P. BOGER, M.D.

AMA Arch Intern Med. 1956;98(4):505-509.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

PROBENECID (Benemid)* has been established as an outstanding uricosuric agent of value in the treatment of chronic gout. The drug has been shown to control hyperuricemia, to cause the diminution in size and even disappearance of tophi, to cause the resolution and repair of bony destructive lesions of gout, to reduce the incidence of acute attacks of gout in the course of the chronic disease, and to increase the sense of well-being in the gouty subject. Indeed, the drug has been called "the insulin of gout" and has been declared to be "the most significant advance in the treatment of gout in many years." Accordingly, the sensitization of a patient to probenecid represents a loss of these potential benefits, especially to the patient who has seen his gout improve even to the point of disappearance of tophi, and it is a loss to which the patient can reconcile himself only . . . [Full Text PDF of this Article]

Author Affiliations
Baltimore; Norristown, Pa.

Footnotes
Received for publication April 13, 1956.

Associate Professor Emeritus of Medicine, The Johns Hopkins University School of Medicine (Dr. Austrian), and Associate in Medicine, University of Pennsylvania School of Medicine, Director of Research Therapeutics, Norristown State Hospital (Dr. Boger).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?